10568255

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				Filing	Filing Date			2006-02-13				
				First	First Named Inventor ZHZ			ANQI LIU,	et	al.		
				Art U	Art Unit							
				Exam	Examiner Name							
				Attor	ney Doc	ket Numbe	er	040000-0360741				
								<u> </u>				
					U.S.	PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1							,				
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation p	lease click t	he A	dd button.				
			U.S.P	ATENT	APPLI	CATION PL	JBLI	CATIONS				
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1											
If you wish	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n informatio	n ple	ease click the Add	d butte	on.		
				FOREIG	GN PAT	ENT DOC	JME	NTS				
Examiner Initial*	raminer Cite Foreign Document Country tial* No Number³ Code² i			Kind Code4	Publication Applica		Name of Patentee Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Т5		

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Cite Initials*

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.

T5

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

1	
Application Number	10568255
Filing Date	2006-02-13
First Named Inventor	ZHANQI LIU, et al.
Art Unit	
Examiner Name	
Attorney Docket Number	er 040000-0360741

	1	Bhattacharya-Chatterjee, M., S. K. Chatterjee, et al. (2001). "The anti-idiotype vaccines for immunotherapy. "Curr Opin Mol Ther 3 (1): 63-9.	
	2	Brown, G. and N. Ling (1988). Murine Monoclonal Antibodies. Antibodies. Volume 1. A Practical Approach. D. Catty. Oxford, England, RL Press: 81-104.	
	3	Clark, M. (2000). "Antibody humanization: a case of the Emperor's new clothes'?" Immunol Today 21 (8): 397-402.	
	4	Clarke, K., F. T. Lee, et al. (2000a)."In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice." Cancer Res 60 (17): 4804-11.	
	5	Clarke, K., F. T. Lee, et al. (2000b). "Therapeutic efficacy of anti-Lewis (y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy."Clin Cancer Res 6 (9): 3621-8.	
	6	Fields, B. A. , F. A. Goldbaum, et al. (1995)."Molecular basis of antigen mimicry by an anti-idiotope. "Nature 374 (6524): 739-42.	
	7	Glennie, M. J. and P. W. Johnson (2000)."Clinical trials of antibody therapy."Immunol Today 21 (8) : 403-10.	
	8	Gruber, R., L. J. van Haarlem, et al. (2000). "The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody C017-1A."Cancer Res 60 (7): 1921-6.	
	9	Hoffman, E. W., A. M. Scott, et al. (2001). Phase I trials of CDR-grafted humanized monoclonal antibody hu3S193 in patients with Lewis-Y expressing solid tumors ASCO 37th Annual Meeting, San Francisco.	
	10	Jerne, N. K. (1974). "Towards a network theory of the immune system."Ann immunol (Paris) 125C (1-2): 373-89.	
1	11	Kim, Y. S., M. Yuan, et al. (1986). "Expression of LeY and extended LeY blood group- related antigens in human malignant, premalignant, and nonmalignant colonic tissues. "Cancer Res 46 (11): 5985-92.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10568255					
Filing Date	2006-02-13					
First Named Inventor	ZHANQI LIU, et al.					
Art Unit						
Examiner Name						
Attorney Docket Number	040000-0360741					

		•					
	12	tamura, K. , E. Stockert, et al. (1994). "Specificity analysis of blood group Lewis-y (Le (y)) antibodies eneratedagainst synthetic and natural Le (y) determinants." Proc Natl Acad Sci U S A 91 (26) : 12957-61.	12 Kita gen				
	13	Liu, Z. , F. E. Smyth, et al. (2002)."Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. " Cancer Immunol mmunother 51 (3): 171-7.					
	14	er, G., L. S. Cohen, et al. (2001)."Serological analysis of human anti-human antibody responses in colon cancer ents treated with repeated doses of humanized monoclonal antibody A33."Cancer Res 61 (18): 6851-9.					
	15	Safa, M. M. and K. A. Foon (2001)."Adjuvant immunotherapy for melanoma and colorectal cancers. "Semin Oncol 28 (1): 68-92.					
	16	amoto, J. , K. Furukawa, et al. (1986). "Expression of Lewisa, Lewisb, X, and Y blood group antigens in human nic tumors and normal tissue and in human tumor- derived cell lines."Cancer Res 46 (3): 1553-61.					
	17	Scott, A. M., D. Geleick, et al. (2000). "Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. "Cancer Res 60 (12): 3254-61.					
	18	Steffens, M. G., O. C. Boerman, et al. (1997). "Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250."J Clin Onco1 15 (4): 1529-37.					
	19	Uemura, H. , E. Okajima, et al. (1994)."Internal image anti-idiotype antibodies related to renal-cell carcinoma- associated antigen G250."Int J Cancer 56 (4): 609-14.					
	20	Zhang, S., C. Cordon-Cardo, et al. (1997)."Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides."Int J Cancer 73 (1): 42-9.					
If you wish to add additional non-patent literature document citation information please click the Add button							
EXAMINER SIGNATURE							
Examiner Signature Date Considered							
		If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a not considered. Include copy of this form with next communication to applicant.					